Copyright
©The Author(s) 2017.
World J Gastroenterol. Jul 14, 2017; 23(26): 4675-4688
Published online Jul 14, 2017. doi: 10.3748/wjg.v23.i26.4675
Published online Jul 14, 2017. doi: 10.3748/wjg.v23.i26.4675
Table 1 Baseline cancer biomarkers shown in preliminary analysis of the Screening Patients for Efficient Clinical Trial Access in advanced colorectal cancer’s molecular screening platform
| KRAS WT | KRAS exon 2 mutated | KRAS exon 3 and exon 4 mutated |
| 151 of 284 patients (53%) | 114 patients in exon 2 (40%) | 8 patients in exon 3 (3%), 11 patients in exon 4 (4%) |
| NRAS mutated (KRAS WT) | PI3KCA | BRAF |
| 14 patients (4.9%); 6 patients in exon 2 and 8 patients in exon 3 | 41 patients (15%), 13 in exon 20 and 28 in exon 9 | 18 patients in exon 15 (7%) |
- Citation: Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World J Gastroenterol 2017; 23(26): 4675-4688
- URL: https://www.wjgnet.com/1007-9327/full/v23/i26/4675.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i26.4675